World game at war: why some European nations have threatened a World Cup boycott 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
 - EconoTimes)
MONTREAL, May 01, 2018 -- Theratechnologies Inc. (Theratechnologies) (TSX:TH) today announced that the Food and Drug Administration (FDA) has released Theratechnologies from post-approval commitments related to the approval of EGRIFTA®.
At the time of approval of EGRIFTA® on November 10, 2010, the FDA requested that the company conduct two large safety clinical trials.
The FDA determined that these two large-scale post-approval clinical trials are no longer required as the current labeling adequately reflects the safety profile of EGRIFTA®. The FDA also concluded that the size of the HIV patient population with lipodystrophy did not make such a requirement feasible.
In its most recent audited financial statements, for the year ended November 30, 2017, Theratechnologies estimated that the post-approval commitments would require an additional investment of US$13 million, which will no longer be required.
About Theratechnologies
Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs to promote healthy living and an improved quality of life among HIV patients. Further information about Theratechnologies is available on the Company's website at www.theratech.com and on SEDAR at www.sedar.com.
Media inquiries:
Denis Boucher
Vice President, Communications and Corporate Affairs
Tel.: (514) 336-7800, ext. 236
